Menu Search
Equities

Heron Therapeutics Inc

AXD2:MUN

Heron Therapeutics Inc

Actions
  • Price (EUR)1.65
  • Today's Change0.000 / 0.00%
  • Shares traded--
  • 1 Year change+186.61%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

  • Revenue in USD (TTM)136.36m
  • Net income in USD-48.13m
  • Incorporated1987
  • Employees126.00
  • Location
    Heron Therapeutics Inc4242 Campus Point Court, Suite 200SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 251-4400
  • Websitehttps://www.herontx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.